nach oben

Erschienen in:

01.04.2015 | Original Article

Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy

verfasst von: Yu Yang, Yang Du, Wu-Xia Luo, Cong Li, Ye Chen, Ke Cheng, Jing Ding, Yi Zhou, Jun Ge, Xian Yang, Ji-Yan Liu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objectives of this study were to investigate the incidences of hepatitis B virus (HBV) reactivation and hepatitis in gastrointestinal cancer patients with positive hepatitis B surface antigen (HBsAg) after chemotherapy and assess the effect of antiviral therapy on preventing HBV reactivation and hepatitis.

Methods

The medical records of gastric or colorectal cancer patients with positive HBsAg undergoing chemotherapy in West China Hospital were reviewed from January 2009 to August 2014.

Results

One hundred and fifty-six patients were included. Seventy-six patients had no records of the baseline HBV DNA copy (bHDC) and received no antiviral therapy. Of 80 patients with known bHDCs, 39 patients received antiviral therapy. The incidence of HBV reactivation was 14.6 % in the non-antiviral group with known bHDCs (n = 41), compared with 0 % in the antiviral group (P = 0.039). Compared with 12.8 % in the antiviral group (P = 0.034), 29.9 % of patients suffered from hepatitis in the total non-antiviral group (n = 117). More patients with moderate/severe hepatitis were seen in the non-antiviral group (P = 0.027). Non-antiviral therapy was the only risk factor for hepatitis in multivariate analysis (HR 3.195, 95 % CI 1.117–10.989; P = 0.043).

Conclusions

HBV reactivation and hepatitis occurred in a significant proportion of gastrointestinal cancer patients with positive HBsAg who received chemotherapy. Antiviral therapy could reduce the incidences of HBV reactivation and hepatitis.

Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J et al (2005) A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Zhonghua Liu Xing Bing Xue Za Zhi 26:655–658PubMed

Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188PubMed

Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ et al (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320–1328CrossRefPubMed

Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS et al (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742–1749CrossRefPubMed

Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 83:270–275CrossRefPubMed

Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF et al (2008) A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 47:844–853CrossRefPubMed

Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH et al (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553–561CrossRefPubMed

Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ et al (2004) Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88:209–215CrossRefPubMed

Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE et al (2011) Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer 104:559–563CrossRefPubMedCentralPubMed

10.

Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 78:2210–2215CrossRefPubMed

11.

Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307CrossRefPubMed

12.

Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI et al (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927–934CrossRefPubMed

13.

Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM et al (2004) Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306–1311CrossRefPubMedCentralPubMed

14.

Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108:1931–1935CrossRefPubMedCentralPubMed

15.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed

16.

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072CrossRefPubMed

17.

Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefPubMed

18.

Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209–220CrossRefPubMed

19.

Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK et al (2005) Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 28:379–384CrossRefPubMed

20.

Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW et al (2006) A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43:233–240CrossRefPubMed

21.

Lin GN, Peng JW, Xiao JJ, Liu DY, Xia ZJ (2014) Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Med Oncol 31:119CrossRefPubMed

22.

Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R (2008) Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral Hepat 15:89–102PubMed

23.

Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528CrossRefPubMedCentralPubMed

24.

Martyak LA, Taqavi E, Saab S (2008) Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 28:28–38CrossRefPubMed

Titel: Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy
verfasst von: Yu Yang
Yang Du
Wu-Xia Luo
Cong Li
Ye Chen
Ke Cheng
Jing Ding
Yi Zhou
Jun Ge
Xian Yang
Ji-Yan Liu
Publikationsdatum: 01.04.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2015
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2700-4

Springer Medizin

Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy